Key Highlights

  • During the morning session on October 14, 2026, AngioDynamics (NASDAQ:ANGO) was 3.35% higher at USD 11.27, with 108,742 shares traded in the partial-session data. No company announcement dated October 14 was identified as a direct catalyst.
  • AngioDynamics reported on October 8, 2026 that fiscal 2027's first-quarter net sales had increased 6.9% to USD 80.9 million. Med Tech contributed USD 39.9 million, up 13.2%, while Med Device generated USD 41.0 million, a 1.4% increase.
  • For the quarter, GAAP results showed a USD 7.1 million net loss, equivalent to USD 0.17 per share; adjusted EBITDA was USD 5.0 million. As of August 31, 2026, cash stood at USD 34.0 million and the company reported no debt.
  • Management maintained its fiscal 2027 ranges of USD 336.0 million to USD 341.0 million in net sales and USD 13.0 million to USD 16.0 million in adjusted EBITDA. Eric Honroth is due to take over as chief executive on November 2, 2026.

Why the Stock Moved

With no company release dated October 14 identified, the 3.35% advance followed the October 8 quarterly update rather than a newly announced development. Product trends were mixed but generally stronger: Auryon atherectomy revenue climbed 14.7% to USD 18.9 million, NanoKnife irreversible electroporation revenue gained 29.0% to USD 8.3 million, and AlphaVac mechanical thrombectomy sales increased 37.4%; AngioVac sales, by contrast, slipped 5.9%. A relative strength reading near 24 placed the shares in oversold territory, which can contribute to a rebound alongside fundamental news. The morning's partial volume of 108,742 shares was limited, so relatively few orders could have had an outsized effect on the quote.

Full-Year Targets and Financial Position

The fiscal 2027 outlook still calls for Med Tech growth of 12% to 15%, flat Med Device sales, a 54% to 55% gross margin, and adjusted EPS between negative USD 0.29 and negative USD 0.24. The USD 5.0 million adjusted EBITDA result differs materially from the GAAP loss of USD 7.1 million, highlighting the effect of items excluded from the adjusted measure. With USD 34.0 million of cash and no debt, the balance sheet provides some flexibility, but the business remains loss-making and must achieve the full-year adjusted EBITDA target of USD 13.0 million to USD 16.0 million. After Q1, management left all guidance ranges unchanged rather than lifting its forecast.

Key Risks and Upcoming Events

Investors will need to assess the leadership handover, competition in vascular and oncology devices, and whether newer products can sustain growth. Eric Honroth is scheduled to replace Jim Clemmer as president and chief executive on November 2, 2026; the transition may prompt questions about strategic priorities. The FDA has authorized the RELIEF investigational-device-exemption study evaluating NanoKnife for benign prostatic hyperplasia, but this remains a clinical-stage opportunity rather than established revenue. The fiscal 2027 second-quarter reporting date was not available at publication. Rivals with bigger sales teams or clinical evidence in peripheral atherectomy and thrombectomy could constrain pricing, while the 5.9% decline in AngioVac sales is a reminder that performance is not uniform across the portfolio. This is informational context, not investment advice.

Current Takeaway

AngioDynamics gained 3.35% on October 14, 2026 without a same-day company announcement. The move came after fiscal Q1 2027 sales rose 6.9% and management reaffirmed its outlook on October 8. An oversold technical reading and the upcoming CEO change add context, but the company remains loss-making and the next fiscal Q2 reporting date is still unannounced. This is not investment advice.